These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

461 related items for PubMed ID: 16150480

  • 1. The results of treatment of epithelial ovarian cancer after centralisation of primary surgery. Results from North Jutland, Denmark.
    Soegaard Andersen E, Knudsen A, Svarrer T, Lund B, Nielsen K, Grove A, Tetsche M.
    Gynecol Oncol; 2005 Dec; 99(3):552-6. PubMed ID: 16150480
    [Abstract] [Full Text] [Related]

  • 2. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
    Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY.
    Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
    [Abstract] [Full Text] [Related]

  • 3. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease.
    Hou JY, Kelly MG, Yu H, McAlpine JN, Azodi M, Rutherford TJ, Schwartz PE.
    Gynecol Oncol; 2007 Apr; 105(1):211-7. PubMed ID: 17239941
    [Abstract] [Full Text] [Related]

  • 4. Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up.
    Akeson M, Zetterqvist BM, Dahllöf K, Brännström M, Horvath G.
    Acta Obstet Gynecol Scand; 2008 Apr; 87(12):1343-52. PubMed ID: 18951208
    [Abstract] [Full Text] [Related]

  • 5. Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study.
    Ansquer Y, Leblanc E, Clough K, Morice P, Dauplat J, Mathevet P, Lhommé C, Scherer C, Tigaud JD, Benchaib M, Fourme E, Castaigne D, Querleu D, Dargent D.
    Cancer; 2001 Jun 15; 91(12):2329-34. PubMed ID: 11413522
    [Abstract] [Full Text] [Related]

  • 6. Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma.
    Safra T, Menczer J, Bernstein RM, Shpigel S, Matcejevsky D, Inbar MJ, Golan A, Grisaru D, Levy T.
    Gynecol Oncol; 2009 Aug 15; 114(2):215-8. PubMed ID: 19446318
    [Abstract] [Full Text] [Related]

  • 7. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Wimberger P, Lehmann N, Kimmig R, Burges A, Meier W, Du Bois A, Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.
    Gynecol Oncol; 2007 Jul 15; 106(1):69-74. PubMed ID: 17397910
    [Abstract] [Full Text] [Related]

  • 8. The clinical significance of malignant pleural effusions in patients with optimally debulked ovarian carcinoma.
    Eitan R, Levine DA, Abu-Rustum N, Sonoda Y, Huh JN, Franklin CC, Stevens TA, Barakat RR, Chi DS.
    Cancer; 2005 Apr 01; 103(7):1397-401. PubMed ID: 15726548
    [Abstract] [Full Text] [Related]

  • 9. Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
    Pectasides D, Fountzilas G, Aravantinos G, Kalofonos HP, Efstathiou E, Salamalekis E, Farmakis D, Skarlos D, Briasoulis E, Economopoulos T, Dimopoulos MA.
    Gynecol Oncol; 2005 May 01; 97(2):436-41. PubMed ID: 15863142
    [Abstract] [Full Text] [Related]

  • 10. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease.
    Ho CM, Huang YJ, Chen TC, Huang SH, Liu FS, Chang Chien CC, Yu MH, Mao TL, Wang TY, Hsieh CY.
    Gynecol Oncol; 2004 Jul 01; 94(1):197-203. PubMed ID: 15262142
    [Abstract] [Full Text] [Related]

  • 11. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer.
    Gadducci A, Iacconi P, Cosio S, Fanucchi A, Cristofani R, Riccardo Genazzani A.
    Gynecol Oncol; 2000 Dec 01; 79(3):344-9. PubMed ID: 11104603
    [Abstract] [Full Text] [Related]

  • 12. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
    Cicin I, Saip P, Eralp Y, Selam M, Topuz S, Ozluk Y, Aydin Y, Topuz E.
    Gynecol Oncol; 2008 Jan 01; 108(1):136-40. PubMed ID: 17936342
    [Abstract] [Full Text] [Related]

  • 13. Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study.
    Chan JK, Tian C, Teoh D, Monk BJ, Herzog T, Kapp DS, Bell J.
    Gynecol Oncol; 2010 Mar 01; 116(3):307-11. PubMed ID: 19944452
    [Abstract] [Full Text] [Related]

  • 14. [Neo-adjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer treatment--a retrospective study].
    Tkácová M, Vertaková-Krakovská B, Belohorská B, Miskovská V, Helpianska L, Ondrus D, Ondrusová M, Spánik S, Svec J.
    Klin Onkol; 2009 Mar 01; 22(6):273-7. PubMed ID: 20099745
    [Abstract] [Full Text] [Related]

  • 15. Impact of age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Wimberger P, Lehmann N, Kimmig R, Burges A, Meier W, Hoppenau B, du Bois A, AGO-OVAR.
    Gynecol Oncol; 2006 Feb 01; 100(2):300-7. PubMed ID: 16199079
    [Abstract] [Full Text] [Related]

  • 16. Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer.
    Vergote I, Amant F, Kristensen G, Ehlen T, Reed NS, Casado A.
    Eur J Cancer; 2011 Sep 01; 47 Suppl 3():S88-92. PubMed ID: 21944035
    [Abstract] [Full Text] [Related]

  • 17. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
    Kim HS, Park NH, Chung HH, Kim JW, Song YS, Kang SB.
    Onkologie; 2008 Jun 01; 31(6):315-20. PubMed ID: 18547972
    [Abstract] [Full Text] [Related]

  • 18. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis.
    Bristow RE, Chi DS.
    Gynecol Oncol; 2006 Dec 01; 103(3):1070-6. PubMed ID: 16875720
    [Abstract] [Full Text] [Related]

  • 19. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study.
    Eisenkop SM, Friedman RL, Wang HJ.
    Gynecol Oncol; 1998 May 01; 69(2):103-8. PubMed ID: 9600815
    [Abstract] [Full Text] [Related]

  • 20. Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients.
    Rocconi RP, Straughn JM, Leath CA, Kilgore LC, Huh WK, Barnes MN, Partridge EE, Alvarez RD.
    Oncologist; 2006 Apr 01; 11(4):336-41. PubMed ID: 16614229
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.